A Phase 3 interventional study of VEGF Trap-Eye (BAY86-5321) and VEGF Trap-Eye (BAY86-5321) in Diabetes Mellitus and Macular Edema, sponsored by Bayer. Completed at 73 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-27.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Diabetes Mellitus by Bayer — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Bayer.
Among the 18 studies in Diabetes Mellitus by Bayer, this one is the only one that started in 2011, is one of 4 in phase 3, and was the 8th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →None of the 18 studies in Diabetes Mellitus by Bayer is open now. The open studies under Diabetes Mellitus, anywhere →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 406 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 406 across the 5 interventional studies, 1,882 across the 13 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Diabetes Mellitus by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular edema (DME) with central involvement
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
Biological: VEGF Trap-Eye (BAY86-5321)
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
Biological: VEGF Trap-Eye (BAY86-5321)
Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
Procedure: Macular Laser Photocoagulation (Control)
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)
Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
Time frame: Baseline up to Week 52
Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
Time frame: Baseline up to Week 52
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF
Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
Time frame: Baseline up to Week 52
Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF
Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)
Time frame: Baseline up to Week 52
Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF
Time frame: Baseline up to Week 52
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
Time frame: Baseline up to Week 52
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.
Time frame: Baseline up to Week 52
Participants with diabetic macular edema (DME) secondary to diabetes mellitus involving the center of the macula in the study eye could participate in the study. The study was conducted at 73 study centers in Japan, European Countries and Australia between 09 May 2011(first participant first visit) and 30 Mar 2015 (last participant last visit).
| Milestone | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation (Control) |
|---|---|---|---|
| Started | 136 | 135 | 135 |
| Participants received treatment | 136 | 135 | 133 |
| Completed week 52 | 125 | 121 | 115 |
| Completed week 100 | 115 | 110 | 105 |
| Completed week 148 | 101 | 101 | 100 |
| Completed | 101 | 101 | 100 |
| Not completed | 35 | 34 | 35 |
| Withdrew: Adverse event | 10 | 13 | 10 |
| Withdrew: Death | 6 | 6 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 12 | 8 | 15 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 4 | 1 |
| Withdrew: Physician decision | 2 | 0 | 4 |
| Withdrew: Therapeutic procedure required | 1 | 0 | 0 |
| Withdrew: Sponsor decision | 1 | 1 | 0 |
| Withdrew: Switching to other therapy | 0 | 0 | 1 |
| Withdrew: Not received study treatment | 0 | 0 | 2 |
Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
| Letters correctly read | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Control |
|---|---|---|---|
| Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF) | 10.5 ± 9.55 | 10.7 ± 9.32 | 1.2 ± 10.65 |
Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
| Percentage of participants | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Control |
|---|---|---|---|
| Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF | 54.4 | 53.3 | 25.8 |
Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning.
| Percentage of participants | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Control |
|---|---|---|---|
| Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF | 32.4 | 33.3 | 9.1 |
Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85)
| Percentage of participants | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Control |
|---|---|---|---|
| Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF | 33.3 | 27.7 | 7.5 |
| micrometer | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Control |
|---|---|---|---|
| Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF | -195.0 ± 146.59 | -192.4 ± 149.89 | -66.2 ± 138.99 |
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf.
| Scores on a scale | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Control |
|---|---|---|---|
| Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF | 5.73 ± 18.932 | 5.29 ± 19.058 | 3.54 ± 16.768 |
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales that are all scored from 0-100. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs.
| Scores on a scale | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Control |
|---|---|---|---|
| Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF | 0.94 ± 16.487 | 5.32 ± 18.475 | 2.26 ± 15.923 |
Collected over For each subject from his first study drug injection until 30 days after the last study drug injection at the latest up to termination visit at Week 148. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravitreal Aflibercept Injection 2Q4 | — | — | 117/136 (86%) |
| Intravitreal Aflibercept Injection 2Q8 | — | — | 122/135 (90.4%) |
| Macular Laser Photocoagulation (Control) | — | — | 113/133 (85%) |
| Event | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation (Control) |
|---|---|---|---|
| CataractEye disorders | 5/136 | 7/135 | 2/133 |
| Myocardial infarctionCardiac disorders | 4/136 | 1/135 | 1/133 |
| Vitreous haemorrhageEye disorders | 4/136 | 1/135 | 2/133 |
| Cerebrovascular accidentNervous system disorders | 4/136 | 1/135 | 1/133 |
| Acute myocardial infarctionCardiac disorders | 2/136 | 0/135 | 3/133 |
| Retinal neovascularisationEye disorders | 1/136 | 0/135 | 3/133 |
| Peripheral arterial occlusive diseaseVascular disorders | 1/136 | 2/135 | 3/133 |
| PneumoniaInfections and infestations | 1/136 | 3/135 | 0/133 |
| Humerus fractureInjury, poisoning and procedural complications | 3/136 | 1/135 | 0/133 |
| Cataract operationSurgical and medical procedures | 3/136 | 1/135 | 2/133 |
| Event | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Macular Laser Photocoagulation (Control) |
|---|---|---|---|
| Conjunctival haemorrhageEye disorders | 43/136 | 39/135 | 17/133 |
| NasopharyngitisInfections and infestations | 38/136 | 39/135 | 34/133 |
| Visual acuity reducedEye disorders | 33/136 | 33/135 | 30/133 |
| Diabetic retinal oedemaEye disorders | 33/136 | 23/135 | 18/133 |
| Visual acuity tests abnormalInvestigations | 19/136 | 22/135 | 32/133 |
| CataractEye disorders | 31/136 | 26/135 | 17/133 |
| Intraocular pressure increasedInvestigations | 28/136 | 18/135 | 16/133 |
| Retinal haemorrhageEye disorders | 21/136 | 25/135 | 21/133 |
| HypertensionVascular disorders | 23/136 | 25/135 | 24/133 |
| Macular oedemaEye disorders | 21/136 | 20/135 | 22/133 |
| Age, Continuous(Years) | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Control | Total |
|---|---|---|---|---|
| Mean | 62.6 ± 8.6 | 64.2 ± 7.8 | 63.9 ± 8.6 | 63.6 ± 8.3 |
| Sex: Female, Male(Participants) | Intravitreal Aflibercept Injection 2Q4 | Intravitreal Aflibercept Injection 2Q8 | Control | Total |
|---|---|---|---|---|
| Female | 53 | 47 | 54 | 154 |
| Male | 83 | 88 | 79 | 250 |
Ran from May 2011 to primary completion in Jun 2013, 24 months.
Results were first posted in Sep 2014, 1 year 3 months after primary completion. A results delay was requested in Mar 2014.
Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 24 months is above that.
Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept